Pancreatic Ductal Adenocarcinoma is difficult to treat in large part due to recurrent mutations in the KRAS gene. Here we define rational treatment approaches to the disease achievable today with existing drug combinations by thorough genetic and pharmacologic dissection of the major KRAS effector pathways; RAF→MEK→ERK and PI3'K→AKT.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) poses a major challenge in oncology due to our inability to diagnose the disease early in its progression, its aggressive clinical behavior and the lack of effective systemic chemotherapy (1). The vast majority of PDAs harbor a mutationally activated form of KRAS (2) . Moreover, KRAS mutation is an early event in PDA, as evidenced by its high prevalence in pancreatic intra-epithelial neoplasia (PanIN) lesions; thought to be a benign precursor to malignant PDA (3) . Furthermore, widespread expression of KRAS G12D throughout the developing mouse pancreas leads to multifocal PanIN formation and, when combined with lesions in p53, to PDA with high frequency in adult mice (4), (5) .
Mutationally activated KRAS binds to a multiplicity of effector proteins including: RAF kinases, PI3'-lipid kinases (PI3K), guanine nucleotide exchange factors for RAL and RHO GTPases respectively (6) .
Since mutationally activated RAS remains an intractable pharmacological target, defining relevant RAS effector pathway(s) in PDA is of considerable clinical importance. Since potent and specific inhibitors of key components of RAS effector pathways are being clinically deployed in a number of malignancies, it has become crucial to understand how best to implement these drugs in the clinical arena for maximal efficacy while minimizing toxicity. Unlike the scenario in melanoma or colorectal cancer, mutational activation of RAS effectors (e.g. BRAF or PIK3CA) is extremely rare in PDA and therefore uninformative as to the key downstream mediators of RAS signaling (7) . This might suggest that numerous RAS effector pathways are essential for PDA and that effective targeting of cancers maintained by mutationally activated KRAS might require concomitant inhibition of two or more RAS effector pathways (8) .
We examined the requirements of the RAF or PI3'K effector arms of KRAS signaling in the initiation, progression and maintenance of PDA using genetically engineered mouse cancer models and cancer (Figures 1A, B) . These lesions were morphologically indistinguishable from those arising in KC mice and of similar grade although were greater in number ( Figure 1C , and not shown). PanINs from BC mice expressed the ductal marker cytokeratin (CK) 19 ( Figure 1D ), Ki67 (a marker of proliferation) ( Figure 1E ) and had abundant phosphorylated nuclear ERK1/2 ( Figure 1F ) indicating activation of the RAF→MEK→ERK pathway. Additionally, whereas primary cilia were observed in both pancreatic islets and normal ducts, PanIN cells from BC mice lacked primary cilia ( Figure 1G , H), consistent with previous findings in KRAS G12D -induced induced PanIN lesions (12) . Six BC mice aged to one year showed no evidence of PDA upon euthanasia.
To test the ability of activated PI3'-kinase-α to initiate PanIN formation we generated (data not shown).
Histologic examination of these cancers showed them to be moderately differentiated PDA displaying robust proliferation (Ki67, Figure 2F ), heterogeneous CK19 expression ( Figure 2G ) and abundant phosphorylated ERK ( Figure 2H ). All mice succumbed to disease within a year ( Figure 2I ). Interestingly, both BRAF V600E -induced PanINs and PDAs displayed abundant stroma and a desmoplasia similar to that seen with in the human disease. We concluded that oncogenic BRAF V600E substitutes for most, if not all, of the oncogenic functions of KRAS G12D in the initiation and progression of PDA in the mouse.
Bioavailability of MEK1/2 Inhibitor PD325901 in PDA
The above results suggested to us that while mutant KRAS can serve many oncogenic functions in cancer, activation of the RAF pathway alone satisfied a genetic sufficiency argument for the PanIN and PDA initiation. To translate this finding into a more clinically relevant hypothesis, we next considered the clinical use of MEK inhibitors, and potential barriers to successful trials with these agents in PDA. It has been recently reported that chemotherapeutic agents are excluded from PDA tissue due to poor drug perfusion into the primary tumor, which is in turn attributable to poor tumor vascularization (14), (15 Figure 1) , ascites, cachexia, and bowel obstruction requiring euthanasia at five to six weeks post implantation. The predictable kinetics and quantifiable tumor implantation allowed for relatively economical drug efficacy studies, as compared to the autochthonous model (17) . Treatment with GSK1120212 led to a decrease in phosphorylation of ERK, rpS6, and 4EBP1 (Thr37/46). GSK690693 treatment led to an expected increase in AKT phosphorylation and suppression of phosphorylation of the direct AKT target; PRAS40 (Thr246). The combination of the two inhibitors had a more profound inhibitory effect on both rpS6 and 4EBP1 phosphorylation in most of the PDA cell lines compared to single agent treatments ( Figure 4D ). We concluded that while some PDA (20) and sufficient (9) for tumor initiation in lung and agree with the requirement for RAF in RAS-induced skin cancer (21) .
There are numerous inhibitors of RAF→MEK→ERK and PI3'-kinase→PDK→AKT signaling currently in drug development (6) . Our findings support the contraindication of RAF inhibitors in the treatment of cancers driven by mutationally activated RAS proteins due to their lack of efficacy and possible growth stimulatory characteristics (22) . We find that MEK1/2 inhibition has potent anti-tumor activity against human or mouse PDA cell lines and against orthotopically implanted tumors. We observed mostly cytostatic responses following MEK inhibition in vivo and observed induction of AKT signaling in response to MEK inhibition in PDA cells. This suggested a functional feedback loop as observed by others in breast or colorectal cancer lines harboring RAS mutations (23), (24) . Indeed, we found that combined inhibition of MEK and AKT led to synergistic effects in the majority of human PDA cell lines tested, similar to findings in lung cancer (25) . We interpret our findings with those of others to suggest that PDA cells, while relatively resistant to single agent AKT inhibition, appear to consistently recruit this important survival pathway in response to acute MEK inhibition, possibly explaining the synergistic interactions seen with these two classes of agents.
Taken in total these findings emphasize the central role played by RAF MEK ERK signaling in both the genesis and maintenance of PDA. These results are important because, while KRAS remains an undruggable molecule, there are numerous potent kinase inhibitors being developed against the downstream effectors of RAS. However, regimens to structure the combined use of these inhibitors remain to be established. We demonstrate that agents currently in clinical trials show potent synergy in PDA treatment. These findings strongly support the further development of combined MEK and AKT inhibition in PDA, and suggest a clear direction for the implementation of pathway-targeted approaches in this disease with tremendous unmet medical need.
Methods
Mouse Studies: All experiments were approved by the UCSF IACUC. BRaf CA (9) , KRas LSL-G12D (4), (GSK690693:GSK1120212) ratio combinations of drugs, and read as described (16) . IC 50 and synergy assessments were performed using the SYNERGY program R (see Supplemental Methods).
Immunoblotting: Cells were grown to 70% confluence and then either treated with GSK690693 1uM or GSK1120212 200nM for 24 hours. Cells were lysed using RIPA buffer and loaded onto NuPage BisTris SDS gels. Antisera included anti-: phosphoERK1/2, ERK1, phosphoAKT (S473), panAkt, phosphor PRAS40, phosphoS6RP and phospho4EBP1 from Cell Signaling Technology and Beta Actin from Santa Cruz. The LiCor Oddessy system was used to visualize western blots.
Immunohistochemistry and Immunofluorescence: Pancreata were fixed overnight in formalin embedded in paraffin, cut into 5μm sections and placed on slides. Following citrate mediated antigen retrieval, slides were incubated with monoclonal rabbit antibodies against Ki67 (Abcam), pERK1/2 (Cell Signaling Technology) or rat anti-CK19 (Hybridoma Bank at the University of Iowa), p53 sc6243 (Santa Cruz), and anti smooth muscle actin A2547 (Sigma) overnight followed by incubation with biotinylated goat anti-rabbit or goat anti Rat IgG and horseradish peroxidase (Vector). Detection was performed using the DAB chromogen system (Dako). Primary cilia were stained as described (12) . 
